Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Rating of “Hold” by Brokerages

Elanco Animal Health Incorporated (NYSE:ELAN) has earned a consensus rating of “Hold” from the eight brokerages that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $16.43.

ELAN has been the topic of several recent research reports. Barclays boosted their price objective on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, November 8th. Stifel Nicolaus lowered their price target on shares of Elanco Animal Health from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday. Leerink Partnrs raised shares of Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Morgan Stanley lowered Elanco Animal Health from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $17.00 to $15.00 in a research note on Thursday, September 19th. Finally, Leerink Partners initiated coverage on Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price target for the company.

Elanco Animal Health Stock Down 2.3 %

Shares of NYSE:ELAN opened at $11.53 on Friday. Elanco Animal Health has a fifty-two week low of $11.28 and a fifty-two week high of $18.80. The firm’s 50-day simple moving average is $12.69 and its 200-day simple moving average is $13.54. The company has a market cap of $5.70 billion, a price-to-earnings ratio of 28.83, a PEG ratio of 1.96 and a beta of 1.41. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.04 billion. During the same period in the prior year, the company posted $0.18 EPS. The business’s revenue for the quarter was down 3.6% on a year-over-year basis. As a group, equities research analysts predict that Elanco Animal Health will post 0.92 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Commerce Bank increased its position in Elanco Animal Health by 2.2% during the third quarter. Commerce Bank now owns 35,114 shares of the company’s stock worth $516,000 after purchasing an additional 741 shares during the last quarter. HBK Sorce Advisory LLC grew its position in Elanco Animal Health by 9.4% during the second quarter. HBK Sorce Advisory LLC now owns 12,920 shares of the company’s stock valued at $186,000 after acquiring an additional 1,107 shares during the period. Keene & Associates Inc. increased its stake in Elanco Animal Health by 5.7% during the third quarter. Keene & Associates Inc. now owns 22,945 shares of the company’s stock worth $337,000 after acquiring an additional 1,240 shares during the last quarter. Benjamin F. Edwards & Company Inc. raised its holdings in shares of Elanco Animal Health by 337.7% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock worth $26,000 after purchasing an additional 1,361 shares during the period. Finally, M&T Bank Corp lifted its position in Elanco Animal Health by 5.9% during the third quarter. M&T Bank Corp now owns 26,407 shares of the company’s stock valued at $388,000 after buying an additional 1,464 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.